Literature DB >> 17143307

Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk.

Patrick Maison1, Philippe Chanson.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17143307     DOI： 10.1038/ncpendmet0350

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  4 in total

1.  Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?

Authors:  Philippe Chanson; Patrick Maison
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-02

2.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 3.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 4.  Acromegaly.

Authors:  Philippe Chanson; Sylvie Salenave
Journal:  Orphanet J Rare Dis       Date:  2008-06-25       Impact factor: 4.123
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.